For the Quarter Ending December 2022
North America
The domestic Clofazimine market in North America showed signals of decline as the Clofazimine API discussion dropped from October to December 2022. Low trade sentiment and pessimistic end-user demand caused prices to decline throughout the fourth quarter of 2022.
Additionally, the merchants' supplies were sufficient to meet consumer demand. Furthermore, Consumer sentiments were weak due to low demand and rising inflation, which forced market participants to lower their quotations to move the equities. Also, the US supply chain gradually recovered in the second half of Q4 2022 as the economy rebounded and ports significantly decreased after the protracted shipment blockage.
APAC
As the Clofazimine API Ex-Vapi discussion decreased from USD 535855/MT to USD 521803/MT from October to December of 2022 in the Asia-pacific region, the domestic Clofazimine market in India showed signs of declining. Due to low trading sentiments and bearish demand from the end-user sector, the prices were witnessed to drop down throughout Q4 2022. Also, the inventories among the merchants were sufficient to meet consumer demand. The average quarterly declination witnessed was 1.62%. With low demand and rising inflation, consumer sentiments were feeble, forcing the market players to drop their quotations to clear the stocks.
Europe
The fourth quarter of 2022 revealed a consistent deterioration in the Clofazimine market in the European region. Despite rising energy prices and a supply-chain bottleneck, Germany's industrial production rose a little bit in October. Offtakes for the end-user sector were favorable in terms of demand. Trade flow in Germany and the larger eurozone was greater in the fourth quarter of 2022 because of some breathing room, but this does not imply that market fundamentals had balanced. Also, with the nearing festival and impeding holidays, the consumer demand sentiments were stable later the in the month of December, keeping the market weak.
For the Quarter Ending September 2022
North America
In the first half of the third quarter of 2022, Clofazimine's price trends significantly increased and gained momentum. Significant energy materials' rising costs on the upstream price front have put enough pressure on Clofazimine's market prices. Furthermore, a sluggish increase in production levels has been caused by increased costs and persistent material constraints. In addition, the uptick in upstream pricing and gloomy market sentiments despite a limited supply of raw materials and delivery delays were associated with the decrease in demand. As a result, both local and foreign market orders somewhat increased. However, Clofazimine costs in the North American market steadied at the end of the third quarter.
APAC
The third quarter of 2022 has seen a considerable market rise in Clofazimine pricing. Business operations across nations have been significantly damaged by the recurrence of COVID cases in China. The product's domestic market shipment and transportation have been affected due to restricted port mobility. As a result, domestic producers have updated their prices to preserve the balance between supply and demand. Additionally, in the third half of Q3, the regular order from the downstream pharmaceutical companies worsened the traders' perceptions of the Clofazimine market. Additionally, the growing demand from the global market, which has values estimated at INR 45005000/MT with an average quarterly inclination of 2.33%, has contributed to Clofazimine's positive market expansion.
Europe
In the European region, Clofazimine pricing patterns have fluctuated. Due to the strong demand from downstream pharmaceutical companies, Clofazimine spot offers have sharply increased. Significant energy materials are scarce due to supply chain bottlenecks caused by Russia's invasion of Ukraine. Excessive energy costs and a lack of raw materials have hampered pharmaceutical companies' growth and put significant pressure on stock prices. The merchants were cautious about including the growing energy costs in their Clofazimine offerings. Furthermore, According to the observed market environment, the impact of Russia's invasion of Ukraine and the associated geopolitical uncertainties stayed contained and narrowed the gap between imports and exports near the end of the quarter.
For the Quarter Ending June 2022
North America
The price trends of Clofazimine have gained an upward momentum and significantly surged in the first half of the second quarter of 2022. On the upstream price front, the price of significant energy materials has escalated, provoking enough cost pressure on the market values of Clofazimine. Furthermore, the rising costs and sustained material shortage have contributed to an obtuse rise in production levels. In addition, the slowdown in demand was linked to the propelled upstream prices and bearish market sentiments amid constrained raw material supplies and delivery delays. As a result, The order from domestic and international markets rose fractionally. However, towards the end of the second quarter, the prices of Clofazimine stabilized in the North-American region.
APAC
During the second quarter of 2022, Clofazimine prices have demonstrated weak market growth. The resurgence of COVID cases in China has severely impacted business activities across the nations. The constrained port movement has resulted in stockpiling of the product in the domestic market. Thus, domestic manufacturers have revised their quotations to maintain the equilibrium between supply and demand. Furthermore, in the second half of Q2, the subdued demand from the downstream pharmaceuticals firms deteriorated the market sentiments of Clofazimine among the traders. In addition, the limited inquiries from the international market have supported Clofazimine's negative market growth with values accessed at INR 42000090/MT with a quarterly declination of 1.54%.
Europe
The price trends of Clofazimine have oscillated in the European region. The spot offers of Clofazimine have witnessed a steep rise, owing to the robust demand from downstream pharmaceutical firms. The supply chain bottlenecks brought on by Russia's invasion of Ukraine have resulted in the limited availability of significant energy materials. The exorbitant energy prices and shortages of raw materials have impacted the progress of pharmaceutical firms and substantially pressured the stockholder's quotations. The traders were cautious about passing on the rising energy costs in the offers for Clofazimine. Furthermore. as per the observed market scenario, towards the quarter end, the imports fell more sharply than export as the impact of Russia's invasion of Ukraine and the related geopolitical uncertainty remained contained and narrowed the market sentiments.
